Christine Schmid-Tannwald to Neuroendocrine Tumors
This is a "connection" page, showing publications Christine Schmid-Tannwald has written about Neuroendocrine Tumors.
Connection Strength
5.554
-
Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients. Radiol Oncol. 2024 09 01; 58(3):348-356.
Score: 0.698
-
[Imaging of pancreatic neuroendocrine tumors]. Radiologie (Heidelb). 2024 Jul; 64(7):559-567.
Score: 0.695
-
Utility of clinical and MR imaging parameters for prediction and monitoring of response to capecitabine and temozolomide (CAPTEM) therapy in patients with liver metastases of neuroendocrine tumors. Radiol Oncol. 2024 06 01; 58(2):196-205.
Score: 0.690
-
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM. Radiol Oncol. 2023 12 01; 57(4):436-445.
Score: 0.672
-
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Diagn Interv Imaging. 2024 Jan; 105(1):15-25.
Score: 0.655
-
Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol. 2022 Jul; 63(7):877-888.
Score: 0.569
-
[Gastroenteropancreatic endocrine tumors]. Radiologe. 2014 Oct; 54(10):989-97.
Score: 0.356
-
Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging. 2013 Jun; 40(6):897-907.
Score: 0.319
-
Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study. Cancer Imaging. 2026 Aug 25; 26(1).
Score: 0.203
-
Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board. Target Oncol. 2025 Jul; 20(4):715-724.
Score: 0.188
-
Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. Theranostics. 2025; 15(13):6444-6453.
Score: 0.186
-
Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs. Cancer Imaging. 2023 Apr 25; 23(1):41.
Score: 0.161
-
Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. Eur Radiol. 2023 May; 33(5):3416-3424.
Score: 0.160